Canada Markets open in 1 hr 8 mins

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.10000.0000 (0.00%)
At close: 11:17AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.1000
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.1000 - 2.1000
52 Week Range2.1000 - 11.2500
Volume500
Avg. Volume2
Market Cap52.68M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-1.1080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022

    LYON, France, May 13, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21st, 2022 at 9 am CEST at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON.

  • Business Wire

    Poxel Announces Availability of Its 2021 Universal Registration Document

    LYON, France, May 04, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2021 has been filed with the French market authority (Autorité des Marchés Financiers, or AMF).

  • Business Wire

    Poxel Announces Its Participation in Upcoming Scientific Conferences

    LYON, France, April 25, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming scientific conferences in May 2022.